144 0001780408 XXXXXXXX LIVE 0001743881 BridgeBio Pharma, Inc. 001-38959 3160 Porter Drive. Suite 250 Palo Alto CA 94304 650 391-9740 KKR Genetic Disorder L.P. Affiliate Common Stock Goldman Sachs & Co. LLC

200 West Street New York NY 10282

6000000 214080000 189880720 05/12/2025 NASDAQ Common Stock 07/01/2019 Conversion of Series B preferred units into shares of common stock (1) Issuer N 15859312 07/01/2019 Conversion of preferred units (1) Common Stock 07/01/2019 Conversion of Series C preferred units into shares of common stock (1) Issuer N 8215295 07/01/2019 Conversion of preferred units (1) Common Stock 07/01/2019 Conversion of Series D preferred units into shares of common stock (1) Issuer N 10178954 07/01/2019 Conversion of preferred units (1) N KKR Genetic Disorder L.P.

30 Hudson Yards New York NY 10001

Common Stock, $0.001 par value 03/05/2025 6000000 209820000 (1) Prior to the Issuer's initial public offering, KKR Genetic Disorder L.P. purchased 167,716,071 preferred units of BridgeBio Pharma LLC, the predecessor in interest to the Issuer, for aggregate consideration of $170,649,999.58 in a series of financing transactions. Upon completion of the reorganization of BridgeBio Pharma LLC into the Issuer, the preferred units held by KKR Genetic Disorder L.P. were converted into 34,253,561 shares of common stock of the Issuer for no additional consideration. 05/12/2025 KKR Genetic Disorder L.P., By: KKR Genetic Disorder GP LLC, its general partner, By: /s/ Ali Satvat, Vice President